ROUND ROCK, TEXAS, August 21, 2024 –Benuvia Operations, LLC, a leader in the development of innovative pharmaceutical cannabinoid and psychedelic products, is excited to announce a strategic partnership with Bright Green Corporation (Nasdaq: BGXX) to secure a supply of DEA-approved marijuana extracts and plant-based psychedelics. This collaboration marks a significant step in Benevia’s mission to advance the production of high-quality, cGMP-compliant Active Pharmaceutical Ingredients (APIs) across various therapeutic areas.
As the pharmaceutical industry increasingly recognizes the benefits of natural sources, Benuvia is committed to enhancing its product offerings by integrating diverse raw materials into its development pipeline. By utilizing both synthetic and plant-derived sources, Benuvia aims to improve the efficacy and quality of its pharmaceutical products, ensuring they meet the highest industry standards.
Benuvia plans to leverage Bright Green’s state-of-the-art production facility, fully compliant with Good Agricultural and Collection Practices (GACP), Good Manufacturing Practices (GMP), and DEA regulations, to produce cGMP pharmaceutical-grade APIs. This partnership will strengthen Benuvia’s capabilities in developing innovative products, allowing the company to adapt to the evolving market landscape and better serve its customers.
“We are thrilled to partner with Bright Green Corporation, as this collaboration aligns perfectly with our vision of improving patient outcomes through innovative pharmaceutical solutions,” said Joe Giraudo, Director of Supply Chain at Benuvia Operations, LLC. “By integrating high-quality raw materials into our product offerings, we are well-positioned to lead the market in pharmaceutical innovation.”
As Benuvia continues to expand its product portfolio, the company remains dedicated to sustainability and responsible sourcing, utilizing innovative cultivation techniques to ensure the highest quality raw materials.
About Benuvia
Benuvia Operations, LLC is a pioneering leader in the research, development, and commercialization of innovative pharmaceutical products across a wide range of therapeutic areas. Benuvia is committed to improving patient outcomes through rigorous scientific study and quality manufacturing practices. With FDA registration, DEA licensing, and cGMP certification, Benuvia operates at the forefront of the pharmaceutical industry. Benuvia’s flagship product, SYNDROS, is an FDA-approved medication used for the treatment of anorexia associated with weight loss in patients with AIDS and for managing chemotherapy-induced nausea and vomiting.
To learn more, visit www.benuvia.com.
About Bright Green Corporation
Bright Green is one of the few companies authorized by the US government and the New Mexico Board of Pharmacy to grow, manufacture, and sell, legally under federal and state law, Schedule I and II plant-based drugs for research, pharmaceutical applications, and affiliated export. Bright Green’s approval from the U.S. Drug Enforcement Administration gives them the opportunity to advance their vision of improving quality of life through the opportunities presented by cannabis and other plant based derived therapies and more.
To learn more, visit www.brightgreen.us
